Search the Newsreel

Alaunos Therapeutics, Inc. Q2 2026: Revenue $0K, Net loss $988K, EPS $(0.41) — 10-Q Summary

Alaunos Therapeutics, Inc. reported its Q2 2026 financial results, showing no revenue and a reduced net loss of $988K, or $(0.41) diluted net loss per share. The company is advancing its preclinical metabolic programs, with lead oral candidate ALN1003 demonstrating positive results in weight …

Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares

Point72 Asset Management, along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has reported a beneficial ownership of 2,366,453 shares of Design Therapeutics, Inc. (DSGN) common stock, which represents 3.8% of the class, as of June 30, 2026. The filing indicates that while …

Fulcrum Therapeutics (FULC) investor group reduces reported ownership to 0%

An investor group comprising TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu has filed an amended Schedule 13G/A, reporting that their beneficial ownership of Fulcrum Therapeutics (FULC) common stock has been reduced to 0%. The filing indicates they no …

Therapeutics, Inc. (FULC) RA Capital group now reports 0.0% stake

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed an amended Schedule 13G/A for Fulcrum Therapeutics, Inc. (FULC). As of June 30, 2026, the group collectively beneficially owned 0 shares, representing 0.0% of the common stock. This …

Nantahala Capital (QNCX) reports 0% stake in Quince Therapeutics in latest 13G/A

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 0% beneficial ownership in Quince Therapeutics, Inc. as of June 30, 2026. This Schedule 13G/A filing indicates that they hold no shares and possess no voting or dispositive power over …

Kazia Therapeutics (KZIA) investor group reports 4.6% beneficial stake via ADS

Lynwood Opportunities Master Fund, Lynwood Capital Management Inc., and Ben Shapiro have reported a beneficial ownership of 4.6% in Kazia Therapeutics (KZIA) through American Depositary Shares as of June 30, 2026. This stake represents 264,980,500 Ordinary Shares, with each ADS equivalent to 500 Ordinary …

Lynx1 Capital (CCCC) discloses 15.4M-share C4 Therapeutics position with warrant blocker

Lynx1 Capital Management LP and Weston Nichols have disclosed a beneficial ownership of 15,423,691 shares of C4 Therapeutics (CCCC), which includes 8,097,000 shares issuable from warrants. This represents a 9.9% stake in the company, calculated based on 110,567,222 shares outstanding and factoring in a …

RA Capital discloses 9.99% C4 Therapeutics (CCCC) stake with warrant blockers

RA Capital Management and affiliated entities have reported a 9.99% beneficial ownership stake in C4 Therapeutics (CCCC) as of June 30, 2026, totaling 11,383,696 shares. This ownership includes common stock and various warrants (pre-funded, Class A, and Class B) which are subject to "Beneficial …

Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary

Vivos Therapeutics, Inc. reported its second-quarter 2026 financial results, showing revenue of $5.15 million, a 35% increase year-over-year. Despite the revenue growth, the company's net loss attributable to stockholders widened to $5.48 million, though diluted loss per share narrowed to $(0.31) due to an …

Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3

Bicara Therapeutics Inc.'s Chief Financial Officer, Jennifer Larson, has submitted an initial Form 3, indicating her status as an officer but showing no reportable equity holdings or transactions at this time. The filing includes a reference to an attached Exhibit 24, which grants a …

Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson

Bicara Therapeutics Inc. has granted 285,000 stock options to its CFO, Jennifer Larson, on August 12, 2026, with an exercise price of $24.63 per share. These options will vest over time, with 25% vesting on August 12, 2027, and the remainder in equal quarterly …

Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position

Commodore Capital LP and its affiliates, including Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, have disclosed a beneficial ownership of 12,000,000 shares of Relay Therapeutics, Inc. (RLAY) common stock. This stake represents 5.5% of the outstanding common stock, based on 218,531,200 …

Pliant Therapeutics (PLRX): Citadel entities, Kenneth Griffin report 3.5% holding

Citadel-affiliated entities and Kenneth Griffin have reported a beneficial ownership of 3.5% in Pliant Therapeutics (PLRX) common stock through an amended Schedule 13G/A filing. This includes 2,143,426 shares owned by Kenneth Griffin, calculated based on 61,920,249 outstanding shares as of May 8, 2026. Various …

Cerenome (PSTV) burns cash, warns on going concern despite fresh equity

Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have reported an amended passive ownership of 3.6% in CytomX Therapeutics, Inc. (CTMX) common stock, totaling 7,811,033 shares as of June 30, 2026. This stake is held indirectly through an investment fund managed by …

PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake

PureTech Health plc, along with its affiliates, has reported a beneficial ownership of 31.2% in Seaport Therapeutics, Inc., amounting to 16,685,013 shares of Voting Common Stock. This stake is held by PureTech LYT, Inc., with PureTech Health LLC and PureTech Health plc exercising indirect …

Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist

This article highlights three promising penny stocks for investors' watchlists: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite varying financial statuses—from pre-revenue to strong growth—all three companies are presented with an overview of their operations, market capitalization, and key financial health …

Lynx1 Capital discloses 13.1% position in TScan Therapeutics (TCRX) common stock

Alaunos Therapeutics (TCRT) warns on cash runway, Nasdaq compliance and losses

Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock

Vivo Opportunity entities, including Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., have reported beneficial ownership of 9.99% of Pasithea Therapeutics (KTTA) common stock. These holdings comprise a mix of common shares and pre-funded warrants, which include provisions to prevent ownership …

Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results

OnKure Therapeutics (OKUR) investor BVF discloses 8% stake plus 2.15M pre-funded warrants

Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE

Jasper Therapeutics (JSPR) reported a significantly narrowed net loss of $2.8 million in Q2 2026, down from $26.7 million in Q2 2025, largely due to lower operating expenses and substantial other income. The company also announced the completion of its acquisition of Kira Pharmaceuticals …

Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund

Point72 Asset Management and its related entities, including Point72 Capital Advisors, Inc. and Steven A. Cohen, have reported a beneficial ownership of 1,993,837 shares of Janux Therapeutics (JANX) common stock, representing 3.3% of the outstanding class as of June 30, 2026. This stake is …

Iovance Biotherapeutics stock hits 52-week high at 6.94 USD

Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year and reflecting significant market optimism. The company reported strong Q2 2026 earnings, surpassing Wall Street expectations with revenue of $99.31 million and a narrower-than-anticipated adjusted loss, …

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake

Point72 entities, including Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, have reported a 7.6% beneficial stake in Atara Biotherapeutics (ATRA). This stake, totaling 687,718 shares of common stock, is held by Point72 Associates, LLC, an investment fund managed by …

Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss

Jasper Therapeutics (JSPR) announced a net loss of $2.8 million for the second quarter ended June 30, 2026. The company recently acquired Kira Pharmaceuticals, raising approximately $132 million, and anticipates releasing interim data and making regulatory filings for its expanded pipeline assets in late …

Corcept Therapeutics (CORT) CBO reports 17,530-share stock gifts and trust holdings

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported several bona fide gift transactions involving 17,530 shares of the company's common stock on August 12, 2026. These transactions included a direct gift disposition of 11,530 shares and gifts of 3,000 shares each to two …

Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing

Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, have disclosed a 9.69% ownership stake in ADC Therapeutics SA (ADCT) via a 13G filing. As of June 30, 2026, they beneficially own 12,326,184 common shares, held through funds and …

Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants

Vivo funds have disclosed beneficial ownership of 9.99% stakes in SAB Biotherapeutics (SABS) through various entities, including Vivo Opportunity Fund Holdings and Vivo Opportunity Cayman Fund. These stakes comprise common stock, Series B Preferred Stock, and warrants, with built-in blocking provisions ensuring that ownership …

Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS)

Commodore Capital and its related entities have disclosed an 8.95 million share beneficial ownership in SAB Biotherapeutics (SABS), representing a 9.9% stake as of June 30, 2026. This position includes common shares, shares convertible from Series B Preferred Stock, and shares from Tranche 1 …

Quince Therapeutics (QNCX) books $39.6M loss but lifts cash to $116M

MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock

MPM BioImpact LLC has filed an Amendment No. 2 to a Schedule 13G, disclosing a beneficial ownership of 1,299,046 shares of Context Therapeutics Inc. (CNTX) common stock, which represents 1.4% of the outstanding class. The firm holds sole voting and dispositive power over these …

Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway

Actuate Therapeutics (ACTU) reported a narrowed net loss of $4.9 million for Q2 2026 and $10.5 million for the first half of 2026, driven by reduced R&D and G&A expenses. Despite this, the company faces significant going concern doubts as its $4.4 million in …

Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake

Commodore Capital and related filers have disclosed a beneficial ownership of 2.41 million Common Shares, representing an 1.8% stake in Definium Therapeutics (DFTX) as of June 30, 2026. This position includes 2 million existing Common Shares and 410,000 shares acquirable through a pre-funded warrant. …